Administration of a thiol-based chemoprotectant compound

Details Administration of a thiol-based chemoprotectant compound Administration of a thiol-based chemoprotectant compound

2006-04-04

2006-04-04

Kim, Vickie (Department: 1618)

Drug, bio-affecting and body treating compositions

Topical sun or radiation screening, or tanning preparations

C424S401000, C424S070510, C424S078050, C514S772400, C514S008100, C514S922000, C514S558000, C514S561000

Reexamination Certificate

active

07022315

ABSTRACT:
A method of administration of a thiol-based chemoprotectant agent including NAC (N-acetylcysteine) and STS (sodium thiosulfate) that markedly affects biodistribution and protects against injury from diagnostic or therapeutic intra-arterial procedures. A method for treating or mitigating the side effects of cytotoxic cancer therapy for tumors located in the head or neck and brain tumors. The thiol-based chemoprotectant agent is administered intra-arterially with rapid and first pass uptake in organs and tissues other than the liver.

REFERENCES:
patent: 4474759 (1984-10-01), Petrovich
patent: 4961926 (1990-10-01), Gabrilove
patent: 5510101 (1996-04-01), Stroppolo et al.
patent: 5728373 (1998-03-01), Alert et al.
patent: 5906984 (1999-05-01), Capizzi et al.
patent: 5994409 (1999-11-01), Stogniew et al.
patent: 6110891 (2000-08-01), Pusztai et al.
patent: 6455061 (2002-09-01), Richardson et al.
patent: 6573253 (2003-06-01), Stogniew
patent: 6759061 (2004-07-01), Watson et al.
patent: 2003/0157191 (2003-08-01), Kil et al.
patent: 0 624 377 (1994-11-01), None
patent: WO 92/08448 (1992-05-01), None
patent: WO 94/00141 (1994-01-01), None
patent: WO 94/03179 (1994-02-01), None
patent: WO 96/14852 (1996-05-01), None
patent: WO 96/26643 (1996-09-01), None
patent: WO 98/11898 (1998-03-01), None
patent: WO 98/34622 (1998-08-01), None
patent: WO 99/29312 (1999-06-01), None
patent: WO 01/80832 (2001-11-01), None
patent: WO 04/039336 (2004-05-01), None
Patchen et al., “Granulocyte colony -stimulating factor and amifostine(ethyol) . . . ” (abstract only) Seminars in Oncology, 1994, vol. 21(5 suppl. 11), pp. 26-32.
Mohr et al., “Combined treatment of stage IV melanoma patients with amifostine and . . . ”, (abstract only), Melanoma Research, 1998, vol. 8(2), pp. 166-169.
Antonadou et al., “Amifostine reduces radiochemotherapy-induced toxicities in patients with locally . . . ”, (abstract only), Seminars in Oncology, 2003, vol. 30(6 suppl. 18), pp. 2-9.
Alvarado, C.S. et al., “Chemotherapy for Patients with Recurrent or Refractory Neuroblastoma: A POG Phase II Study,”Journal of Pediatric Hematology/Oncology 19(1): 62-67, Feb. 1997.
Blakley, B.W. et al., “Strategies for Prevention of Toxicity Caused by Platinum-Based Chemotherapy: Review and Summary of the Annual Meeting of the Blood-Brain Barrier Disruption Program, Gleneden Beach, Oregon, Mar. 10, 2001,”The Laryngoscope 112(11): 1997-2001, Nov. 2002.
Blay, J.Y. et al., “A Risk Model for Thrombocytopenia Requiring Platelet Transfusion After Cytotoxic Chemotherapy,”Blood 92(2): 405-410, Jul. 15, 1998.
Budd, G.T. et al., “Clinical Effects of Amifostine (Ethyol®) in Patients Treated with Carboplatin,”European Journal of Cancer 32A(Suppl. 4): S43-S45, Oct. 1996.
Butterworth, M. et al., “CysteineIsopropylesterProtects Against Paracetamol-Induced Toxicity,”Biochemical Pharmacology 43(3): 483-488, 1992.
Case, B.C. et al., “The Pharmacokinetics and Pharmacodynamics of GW395058, a Peptide Agonist of the Thrombopoietin Receptor, in the Dog, a Large-Animal Model of Chemotherapy-Induced Thrombocytopenia,”Stem Cells 18: 360-365, 2000.
Dahlborg, S.A. et al., “The Potential for Complete and Durable Response in Nonglial Primary Brain Tumors in Children and Young Adults with Enhanced Chemotherapy Delivery,”The Cancer Journal from Scientific American4(2): 110-124, Mar./Apr. 1998.
Database BIOSIS, STN/CAS Online, Accession No. 2002:129589, Doolittle et al.,Blood 98(11, Part 1):37a-38a, Nov. 2001.
de Jong, R.S. et al., “Phase II Study of Intraperitoneal Cisplatin Plus Systemic Etoposide as Second-line Treatment in Patients With Small Volume Residual Ovarian Cancer,”European Journal of Cancer 31A(5): 709-713, 1995.
Doolittle, N.D. et al., “Delayed Sodium Thiosulfate as an Otoprotectant Against Carboplatin-induced Hearing Loss in Patients with Malignant Brain Tumors,”Clinical Cancer Research7:493-500, Mar. 2001.
Einhorn and Loehrer, “Ifosfamide chemotherapy for pancreatic carcinoma,”Cancer Chemotherapy and Pharmacology 18(Suppl. 2): S51-S54, 1986.
Harker, L.A. et al., “Prevention of Thrombocytopenia and Neutropenia in a Nonhuman Primate Model of Marrow Suppressive Chemotherapy by Combining Pegylated Recombinant Human Megakaryocyte Growth and Development Factor and Recombinant Human Granulocyte Colony-Stimulating Factor,”Blood 89(1): 155-165, Jan. 1, 1997.
Howell, S.B. et al., “Intraperitoneal Cisplatin with Systemic Thiosulfate Protection,”Annals of Internal Medicine 97(6): 845-851, Dec. 1982.
Isaacs, C. et al., “Randomized Placebo-Controlled Study of Recombinant Human Interleukin-11 to Prevent Chemotherapy-Induced Thrombocytopenia in Patients With Breast Cancer Receiving Dose-Intensive Cyclophosphamide and Doxorubicin,”Journal of Clinical Oncology 15(11): 3368-3377, Nov. 1997.
Iwamoto, Y. et al., “‘Two-Route Chemotherapy’ Using High-Dose Ip Cisplatin and Iv Sodium Thiosulfate, Its Antidote, for Peritoneally Disseminated Cancer in Mice,”Cancer Treatment Reports 68(11): 1367-1373, Nov. 1984.
Kim, S. et al., “Dose intensification of cisplatin chemotherapy through biweekly administration,”Annals of Oncology 4: 221-227, 1993.
Muldoon, L.L. et al., “Delayed Administration of Sodium Thiosulfate in Animal Models Reduces Platinum Ototoxicity without Reduction of Antitumor Activity,”Clinical Cancer Research 6:309-315, Jan. 2000.
Muldoon, L.L. et al., “Rescue from Enhanced Alkylator-Induced Cell Death with Low Molecular Weight Sulfur-Containing Chemoprotectants,”The Journal of Pharmacology and Experimental Therapeutics 296(3): 797-805, 2001.
Neuwelt, E.A. et al., “First Evidence of Otoprotection Against Carboplatin-Induced Hearing Loss with a Two-Compartment System in Patients with Central Nervous System Malignancy Using Sodium Thiosulfate,”The Journal of Pharmacology and Experimental Therapeutics 286(1): 77-84, 1998.
Neuwelt, E.A. et al., “In Vitro and Animal Studies of Sodium Thiosulfate as a Potential Chemoprotectant against Carboplatin-induced Ototoxicity,”Cancer Research 56(4): 706-709, Feb. 15, 1996.
Neuwelt, E.A. et al., “Therapeutic Efficacy or Aortic Administration of N-Acetylcysteine as a Chemoprotectant against Bone Marrow Toxicity after Intracarotid Administration of Alkylators, with or without Glutathione Depletion in a Rat Model,”Cancer Research 61:7868-7874, Nov. 1, 2001.
Piperno, E. et al., “Pathophysiology of Acetaminophen Overdosage Toxicity: Implication for Management,”Pediatrics 62(5—Supplement): 880-889, Nov. 1978.
Robbins, K.T. et al., “Efficacy of Targeted Supradose Cisplatin and Concomitant Radiation Therapy for Advanced Head and Neck Cancer: The Memphis Experience,”International Journal of Radiation Oncology Biology Physics 38(2): 263-271, May 1, 1997.
Vermeulen, N.P.E. et al., “Toxicity of fotemustine in rat hepatocytes and mechanism-based protection against it,”Chemico-Biological Interactions 110:139-158, 1998.
Verschraagen, M. et al., “Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites,”Clinical Pharmacology&Therapeutics 74(2): 157-169, Aug. 2003.
Wheeler, B.M. et al., “Ifosfamide in Refractory Male Germ Cell Tumors,”Journal of Clinical Oncology 4(1): 28-34, Jan. 1986.
Iwamoto, et al., “Inactivation of cis-diamminedichloroplatinum(II)in blood and protection of its toxicity by sodium thiosulfate in rabbits,” Cancer Chemother. Pharmacol. 15(3):pp228-32 (1985).
Kobayashi, et al., “Therapeutic efficacy of two-route chemotherapy using cis-diamminedichloroplatinum(II)and its antidote, sodium thiosulfate, combined with the angiotensin-II-induced hypertension method in a rat uterine tumor,” Int. J. Cancer 47(6):pp893-8 (Apr. 1, 1991).
Markman, et

Affiliated with

Also associated with

Rating

Administration of a thiol-based chemoprotectant compound does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Administration of a thiol-based chemoprotectant compound, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Administration of a thiol-based chemoprotectant compound will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3593072